eXciteOSA for Obstructive Sleep Apnea
(ELMO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of a device called eXciteOSA for individuals with moderate obstructive sleep apnea (OSA), a condition where breathing stops and starts during sleep. The study compares two usage methods—either two 20-minute sessions or one 30-minute session each day—against no treatment over six weeks. Participants must have a diagnosis of moderate OSA and need a smartphone or tablet to use the device app. As an unphased trial, this study provides participants the chance to contribute to innovative research that could enhance sleep apnea treatment options.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude people who use overnight therapies that can't be stopped during the study and those who chronically use central nervous system depressants. It's best to discuss your specific medications with the trial team.
What prior data suggests that the eXciteOSA device is safe for patients with moderate OSA?
Research has shown that the eXciteOSA device, which uses gentle electrical pulses to strengthen tongue muscles, is generally safe. Studies have found that people with mild obstructive sleep apnea (OSA) usually tolerate this device well. Participants in these studies used the device during the day and found it easy to continue the treatment.
The FDA has approved the device to help reduce snoring and treat mild sleep apnea, indicating it has passed strict safety checks. However, all treatments can have side effects, and individual experiences may vary. It is important to consult a healthcare provider about potential risks and benefits before starting a new treatment.12345Why are researchers excited about this trial?
Researchers are excited about eXciteOSA because it offers a non-invasive approach to treating moderate obstructive sleep apnea, unlike traditional options like CPAP machines or surgical interventions. The treatment uses neuromuscular electrical stimulation, which involves applying mild electrical pulses to strengthen the muscles in the tongue and upper airway, potentially reducing airway blockage. This technique is novel because it targets the root cause of sleep apnea with daily short sessions, potentially leading to better compliance and fewer side effects compared to more cumbersome or invasive methods.
What evidence suggests that the eXciteOSA device is effective for moderate OSA?
Research has shown that the eXciteOSA device can improve sleep apnea symptoms by using gentle electrical stimulation to strengthen muscles. One study found that people using the device experienced a significant improvement in their sleep apnea severity. Specifically, their apnea-hypopnea index (AHI), which measures sleep apnea severity, decreased from 10.2 events per hour to 6.8 events per hour, indicating symptom improvement. Additionally, using this device during the day has reduced snoring, a common issue with sleep apnea. In this trial, participants will be assigned to different treatment arms, including Therapy Dose-A and Therapy Dose-B, to evaluate the effectiveness of eXciteOSA in individuals with moderate obstructive sleep apnea.35678
Who Is on the Research Team?
Yasser Zayni
Principal Investigator
yasser.z@signifiermedical.com
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the eXciteOSA device therapy for six weeks, with two different dosing regimens
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- eXciteOSA
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Neuromuscular electrical stimulation; one 30-minute session per day.
Neuromuscular electrical stimulation; two 20-minute sessions per day.
Under the care of the referring physician, with no therapy applied
Find a Clinic Near You
Who Is Running the Clinical Trial?
Signifier Medical Technologies
Lead Sponsor
Citations
Neuromuscular electrical stimulation for obstructive sleep ...
In this randomised controlled trial, patients with mild obstructive sleep apnoea (OSA) were noted to adhere to daytime neuromuscular electrical stimulation.
New Published Study Explores Cost-Effectiveness of ...
The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no ...
Signifier Medical Technologies Announces Publication of ...
Based on the data from the peer-reviewed analysis, the researchers observed a significant improvement in the apnea-hypopnea index (AHI) from 10.2 to 6.8 events/ ...
eXciteOSA for Treatment of Mild Obstructive Sleep Apnea
The objective of this study is to assess the efficacy of the eXciteOSA device amongst a sample of patients with mild OSA. The study is a multi-center, ...
Daytime Neuromuscular Electrical Therapy of Tongue ...
Daytime NMES (eXciteOSA) is demonstrated to be effective at reducing objective and subjective snoring. It is associated with effective improvement in patient ...
Questions & Answers
eXciteOSA is intended for the reduction of snoring and mild obstructive sleep apnea by strengthening tongue muscles via electrical muscle stimulation.
Neuromuscular tongue muscle stimulator for the reduction of ...
eXciteOSA is a removable tongue muscle stimulation device that delivers neuromuscular stimulation to the tongue in order to reduce snoring and mild obstructive ...
eXciteOSA® Product Information
It received FDA De Novo classification,. DEN200018, on February 5, 2021 and is listed as a neuromuscular tongue muscle stimulator for the reduction of snoring ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.